Authors
Latest:
An Explosion of Agents for Myeloma TreatmentPrerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.
Latest:
Future Perspectives and Unmet Needs in the Treatment of Ovarian CancerChad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.
Latest:
Olaparib Trial Supports 2-Year Treatment Duration in Ovarian CancerWilliam H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
Latest:
CAR T Benefits in Cancer Outweigh Potential Risk of Secondary MalignanciesMatthew J. Frigault, MD, MS, discussed what a community oncologist should know about the ongoing FDA investigation of chimeric antigen receptor T-cell therapies.
Latest:
Addressing How to Treat Patients With Advanced Hepatocellular CarcinomaMehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.
Latest:
Expanding the Use of Targeted Therapies in GISTNeeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.
Latest:
Niraparib Results Encourage Somatic Tumor Profiling in Ovarian CancerMatthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.
Latest:
A Deep Dive Into the Evolving Landscape of Prostate CancerIn season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
Latest:
Challenges Remain in Treating Anaplastic Thyroid CancerYuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.
Latest:
Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s MacroglobulinemiaChristian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Latest:
Questioning When to Start Immunotherapy for Patients With Oncogenic DriversKaren Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
Latest:
Copanlisib and Rituximab Show Efficacy in Follicular LymphomaMark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.
Latest:
Closing Perspectives on MM Treatment and CareBrea C. Lipe, MD closes this series highlighting the vast landscape of effective treatments and those on the horizon.
Latest:
Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
Cristian on the 2023 Miami Cancer Institute Oncology Rehabilitation SymposiumAdrian Cristian, MD, discusses the background of the third annual Miami Cancer Institute Oncology Rehabilitation Symposium and provides an overview of some of the topics that were presented this year.
Latest:
Beyond the First-Line: Economides on Advancing Therapies in RCCIn our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Latest:
Skin Toxicity in Cancer Treatment: A Critical Part of Cancer Supportive CareIn contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.
Latest:
Bispecific Antibodies Look Promising in Follicular LymphomaThe use of bispecific antibodies has the potential to revolutionize the management of FL.
Latest:
Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLCMasahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.
Latest:
MRD Linked to Long-Term Survival With Azacitidine Therapy in AMLAndrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.
Latest:
Future Directions for NK Cell Platforms in Hematologic MalignanciesJeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.
Latest:
Manipulating T Cells to Treat Patients With CancerBruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.
Latest:
HR+/HER2- Metastatic Breast Cancer: Future Directions in CareClosing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Latest:
Exploring Novel Combinations in Indolent LymphomasAlthough chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.
Latest:
Navigating Unmet Needs in SR/D cGvHDDr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Latest:
What’s Next for the HER2-Negative Breast Cancer Space?Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.
Latest:
CAR T and Bispecifics Take Center Stage in New Myeloma TrialsAdam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.
Latest:
Areas of Growth in the Management of EGFR-Mutated Lung CancerLiza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.
